We describe a de novo computational approach for designing proteins that recapitulate the binding sites of natural cytokines, but are otherwise unrelated in topology or amino acid sequence. We use this strategy to design mimics of the central immune cytokine interleukin-2 (IL-2) that bind to the IL-2 receptor βγ c heterodimer (IL-2Rβγ c ) but have no binding site for IL-2Rα (also called CD25) or IL-15Rα (also known as CD215). The designs are hyper-stable, bind human and mouse IL-2Rβγ c with higher affinity than the natural cytokines, and elicit downstream cell signalling independently of IL-2Rα and IL-15Rα. Crystal structures of the optimized design neoleukin-2/15 (Neo-2/15), both alone and in complex with IL-2Rβγ c , are very similar to the designed model. Neo-2/15 has superior therapeutic activity to IL-2 in mouse models of melanoma and colon cancer, with reduced toxicity and undetectable immunogenicity. Our strategy for building hyperstable de novo mimetics could be applied generally to signalling proteins, enabling the creation of superior therapeutic candidates. 1 8 6 | N A t U r e | V O l 5 6 5 | 1 0 J A N U A r Y 2 0 1 9
The considerable potential of the central immune cytokine interleukin-2 (IL-2) for cancer treatment 1-3 has sparked numerous efforts to improve its therapeutic properties by mutation and/or chemical modification 4-11 . Such efforts have sought to simplify manufacturing, extend half-life, and modulate interactions with receptors [12] [13] [14] . However, there are inherent challenges to the development of a new therapeutic agent when starting with a naturally occurring bioactive protein. First, most natural proteins are only marginally stable [15] [16] [17] ; hence, amino acid substitutions aimed at increasing efficacy can decrease expression or cause aggregation, making manufacture and storage difficult. More substantial changes, such as deletion or fusion of functional or targeting domains, are often unworkable and can markedly alter pharmacokinetic properties and tissue penetration 13 . Second, any immune response against the engineered variant may cross-react with the endogenous molecule [18] [19] [20] [21] [22] [23] [24] with potentially dangerous consequences. Third, the target receptor-subunit interaction profile can be difficult to reprogram. The clinical use of IL-2 has been mainly limited by toxicity [25] [26] [27] which, although incompletely understood in humans, is considerably reduced in animals deficient in the IL-2Rα chain (CD25 − ). Previous efforts to ablate the interaction between CD25 and IL-2 by either mutation 5, 8, 28, 29 (as in super-2) or PEGylation (for example, NKTR-214 11 ), have resulted in markedly reduced stability, binding, and/or potency of these reengineered cytokines, while failing to completely eliminate the interaction with CD25. Here we describe a computational design approach to generate mimetics of natural proteins with improved therapeutic properties that circumvent these challenges, allowing the engineering of hyper-stable de novo cytokine mimics that display specific receptor-binding interfaces that are optimal for treating disease.
IL-2/IL-15 mimics that bind and activate IL-2Rβγ c
Cytokines interact with multiple receptor subunits [30] [31] [32] [33] , and like most naturally occurring proteins, contain non-ideal structural features that compromise their stability but are important for function. We developed a computational protein design method in which the structural elements that interact with the desired receptor subunit(s) are fixed in space (Fig. 1a) , and an idealized de novo globular protein structure is built to support these elements. De novo design has been used previously to support short linear epitopes [34] [35] [36] [37] ; here we support more complex binding interfaces by using a parametric construction of disembodied helices coupled with knowledge-based loop closure 38 (Fig. 1b , c). We tested our approach by attempting de novo design of stable idealized proteins with interaction surfaces mimicking those of IL-2 and IL-15 for IL-2Rβγ c 32, 39 , but entirely lacking the CD25interaction surface.
Native IL-2 comprises four helices (Fig. 1a ) connected by long irregular loops. The N-terminal helix (H1) interacts with both the βand γ-subunits, the third helix (H3) interacts with the β-subunit, and the C-terminal helix (H4) interacts with the γ-subunit. The α-subunit (CD25) interacting surface is formed by the irregular second helix (H2) and two long loops, one connecting H1 to H2 and the other connecting H3 to H4. We aimed to build an idealized protein that recapitulates the interface formed by H1, H3 and H4 with β and γ-subunits and to replace H2 with a helix that provides better packing and does not interact with the α-subunit. Two generations of designed mimics were made. In a first generation, we used all helices (H1, H2, H3 and H4) from IL-2 ( Fig. 1a ) as starting points for structure idealization by (independently) rebuilding each disembodied helix using commonly Article reSeArcH occurring protein fragments (see Methods) and connecting helices with fragment-derived loops (Fig. 1c ) to generate fully connected backbones ( Fig. 1d ). Rosetta combinatorial flexible backbone sequence design was carried out [40] [41] [42] for each backbone (in complex with human IL-2Rβγ c ), resulting in a considerably more regular structure for H2 (H2′) than in IL-2 ( Fig. 1b, top; see Methods). The four lowest-energy designs and eight single-disulfide-stapled variants ( Supplementary Table 1) were selected for experimental characterization by yeast display (see Methods). Eight designs bound fluorescently-tagged βγ-chimeric IL-2 receptor at low-nanomolar concentrations ( Supplementary Fig. 1) , and the highest affinity non-disulfide design (G1_neo2_40) was subjected to site-saturation mutagenesis ( Supplementary Table 5 ) and selection for increased affinity to human IL-2Rβγ c . A second round of selection was then carried out on a library combining the best individual affinity-enhancing substitutions (combinatorial library, Supplementary Fig. 2, Supplementary Table 7 ). The highest-affinity variants ( Supplementary Fig. 4 , Supplementary Table 2 ) were expressed recombinantly in Escherichia coli and found to elicit pSTAT5 signalling in vitro on IL-2-responsive mouse cells at low-nanomolar or even picomolar concentrations (Extended Data Table 1), but had relatively low thermal stability (melting temperature, T m < 45 °C, Supplementary  Figs. 3, 5 ). To improve stability, in a second generation of designs, we repeated the computational design protocol starting from the backbone of the highest affinity first-round design (G1_neo2_40_1F, topology: H1→H4→H2′→H3), but this time coupling the loop-building process with parametric variation of the helix lengths (up to ±8 amino acids, Fig. 1b, bottom) . This second-generation approach improved the quality of the models by enabling the exploration of a substantially larger number of combinations of high-quality loops connecting each pair of helices. The 14 second-generation designs with highest predicted affinity and stability, along with 27 Rosetta-sequence redesigns of G1_neo2_40_1F ( Supplementary Table 3 ), were experimentally characterized. All but one of the designs were found to bind the human IL-2 receptor at low-nanomolar concentrations (Fig. 1f , Extended Data Table 1 , Supplementary Fig. 6 ). The three designs with highest affinity and stability (one sequence redesign and two new mimetics) were subjected to site-saturation mutagenesis ( Supplementary Table 6 ), followed by selection on combinatorial libraries of substitutions to increase affinity for mouse IL-2Rβγ c (Supplementary Figs. 8-10 , Supplementary Tables 6, 8) , which yielded higher-affinity hyper-stable variants of the de novo mimics (Extended Data Table 1, Supplementary  Tables 4, 8 , Supplementary Figs. 11-13 ). The second-generation optimized design with highest overall affinity for both human and mouse IL-2Rβγ c , Neo-2/15, is a 100-residue protein with a topology and sequence that is quite different from human or mouse IL-2 (BLASTP sequence identity to human and mouse IL-2 of 14% and 24%, respectively; MICAN structure-based sequence identity to human and mouse IL-2 of 29% and 16% respectively, see Methods and Extended Data Table 1 ).
Functional characterization of Neo-2/15
Neo-2/15 binds with high affinity to human and mouse IL-2Rβγ c (with dissociation constants, K d ≈ 19 nM and K d ≈ 38 nM, respectively), but does not interact with IL-2Rα ( Fig. 2a ). The affinities of Neo-2/15 for the human and mouse IL-2 receptors (IL-2Rβ and IL-2Rβγ c ) are higher than those of the corresponding native IL-2 cytokines (Extended Data Fig. 1 | Computational design of de novo cytokine mimics. a, Structure of human IL-2 (HsIL-2) (cartoon representation) in complex with its receptor IL-2Rαβγ c (surface representation) (Protein Data Bank (PDB) ID: 2B5I). b, The designed mimics have four helices; three (blue, yellow and red) mimic IL-2 interactions with IL-2Rβγ c , whereas the fourth (green) holds the first three in place. Top, first generation (gen 1): each of the core elements of IL-2 (helices H1-H4) were independently idealized by assembly of four residue clustered protein fragments. Bottom, second generation (gen 2): the core elements were built using parametric equations that recapitulate the shape of each disembodied helix, allowing changes in the length of each helix by up to ±8 amino acids. c, Pairs of helices were reconnected using ideal loop fragments; representative examples are shown with the newly built elements connecting each pair of helices in magenta. d, Combination of helix hairpins in c to generate fully connected protein backbones. e, Rosetta flexible backbone sequence design. f, Binding and activity of selected designs (solid symbols), the green arrow originates at the parent of the best optimized design Neo-2/15. (see Extended Data Table 1 ).
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IL-2 (EC 50 = 130 pM versus 30 nM). These results are consistent with the higher binding affinity of Neo-2/15 for the IL-2 receptors ( Fig. 2b , Supplementary Table 9 ). Neo-2/15 is also more active than super-2, a variant of IL-2 engineered for higher affinity for IL-2Rβ 8 , on IL-2Rα − mouse primary T cells (EC 50 = 130 pM versus 660 pM) and less active than super-2 on IL-2Rα + cells (EC 50 = 24 pM versus 1.2 pM), presumably owing to its complete lack of IL-2Rα binding (Fig. 2b ). Neo-2/15 is hyper-stable ( Supplementary Fig. 13 ) and does not lose binding affinity for the IL-2Rβγ c following incubation at 80 °C for 2 h, whereas human IL-2 and super-2 are inactivated after 10 min (half-inactivation time ≈ 4.2 min and 2.6 min, respectively, Fig. 2c , top). In ex vivo primary cell cultures, Neo-2/15 drives T cell survival effectively after 60 min of boiling at 95 °C, whereas these conditions inactivated both IL-2 and super-2 ( Fig. 2c , bottom). This unprecedented stability for a cytokine-like molecule, as well as elimination of the requirement for cold chain storage, suggests a robustness to mutations (Extended Data Fig. 8 ), genetic fusions, and chemical modification ( Supplementary  Fig. 14) greatly exceeding that of native IL-2, which could contribute to the development of improved or new therapeutic properties (Extended Data Figs. 3, 4).
Structure of Neo-2/15 and complex with MmIL-2Rβγ c
The X-ray crystal structure of Neo-2/15 is very similar to the computational design model (root mean square deviation of C α atoms, r.m.s.d. = 1.1-1.3 Å for the 6 copies in the asymmetric unit, Fig. 3a ). We determined the structure of mouse IL-2Rβγ c in complex with Neo-2/15 and found that it aligns very closely to the previously rep orted human IL-2 receptor complex 43 (Fig. 3b , Extended Data Table 2 ). The Neo-2/15 design model and the unbound crystal structure align with the mouse ternary complex structure with r.m.s.d. of 1.27 and 1.29 Å, respectively (Fig. 3c ). The order of helices in Neo-2/15 (using IL-2 numbering) is H1→H3→H2′→H4 ( Figs. 1a, 3a, d) . The H1-H3 loop is disordered in the ternary complex, but helix H3 is in close agreement with the predicted structure; there is also an outward movement of helix H4 and the H2′-H4 loop compared to the monomeric structure ( Fig. 3c ). Neo-2/15 interacts with mouse IL-2Rβ via helices H1 and H3, and with γ c via the H1 and H4 helices ( Fig. 3) ; these regions align closely with both the computational design model ( Fig. 3a ) and the monomeric crystal structure ( Fig. 3c) . A shift of about 4.0 Å for helix H4 (see Fig. 3c ) in the mouse complex may reflect the optimization for high-affinity binding to both the mouse and human receptors. The design of Neo-2/15 was guided by the human complex structure, and simulations suggest that there is little or no helix shift in this complex (Extended Data Fig. 7 ). Consistent with this, the helices of apo Neo-2/15 superimpose closely on those of human IL-2 in complex with its receptor (Fig. 3e , f), despite the different topologies of the two proteins ( Fig. 3d ).
Therapeutic applications of Neo-2/15
The inherent low stability of IL-2 and its tightly evolved dependence on CD25 have been barriers to the clinical translation of re-engineered IL-2 compounds. Other efforts have focused on IL-15 44 , because it elicits similar signalling to IL-2 by dimerizing IL-2Rβγ c , but has no affinity for CD25. However, IL-15 activity is dependent on trans presentation of IL-15Rα, which is displayed primarily on antigen-presenting cells and NK cells. The low stability of native IL-15 and its dependence on trans presentation have also presented substantial barriers to re-engineering efforts 44, 45 .
Dose-escalation studies on naive mice show that Neo-2/15 causes lower expansion of immunosuppressive T regulatory (T reg ) cells than mouse IL-2 ( Fig. 4a , left), leading to a higher CD8 + killer T cell:T reg ratio with Neo-2/15 ( Fig. 4a, right) . The increased expansion of T reg cells by mouse IL-2 is expected, because it binds preferentially to CD25 + cells 35, 46, 47 . The higher CD8 + T cell:T reg ratios achieved with Neo-2/15 are generally associated with better tumour killing 8, 11, 29 ; this functional advantage of Neo-2/15 is likely to stem from its higher affinity for IL-2Rβγ c and lack of bias towards CD25 + cells. Similarly, in a mouse model of airway inflammation that normally induces a small percentage of tissue-resident CD8 + T cells (Thy1.2 − CD44 + CD8 + ), Neo-2/15 elicits an increase in the population of tissue-resident CD8 + T cells without increasing the population of antigen-specific T reg (CD4 + Foxp3 + ; Fig. 4b ). 
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To test whether Neo-2/15 is immunogenic, naive and tumour-bearing mice were treated with Neo-2/15 daily (over a period of 4 weeks and 2 weeks, respectively). Little or no immunogenicity was observed in either case ( Fig. 4c , Extended Data Fig. 5 ). A similar lack of immune response has been observed for other de novo-designed therapeutic candidates 35 (probably owing to their small size and high stability). Polyclonal antibodies against Neo-2/15 were generated by vaccinating mice with an inactive Neo-2/15 mutant-Neo-2/15(Y14D/F99D), also known as KO Neo-2/15-in complete Freund's adjuvant. These polyclonal Neo-2/15 antibodies do not cross-react with human or mouse IL-2 ( Fig. 4c , Extended Data Fig. 5 ), suggesting that even if there is an immune response to Neo-2/15 in a therapeutic setting, this response is unlikely to cross-react with endogenous IL-2. This is consistent with the low sequence identity between Neo-2/15 and human or mouse IL-2 (Extended Data Table 1), which makes an autoimmune response against host IL-2 much less likely with Neo-2/15 than with previously engineered human IL-2 variants (for example, super-2 or PEGylated IL-2), which differ from endogenous IL-2 by only a few mutations (the BLASTP sequence identities of Neo-2/15 and super-2 to human IL-2 are 14% and 95%, respectively).
We tested the therapeutic efficacy of Neo-2/15 in B16F10 (melanoma) and CT26 (colon cancer) mouse models. Single-agent treatment with Neo-2/15 led to dose-dependent delays in tumour growth in both cancer models. In CT26 colon cancer, single-agent treatment showed improved efficacy compared to mouse IL-2 ( Fig. 4d , Extended Data Fig. 1 ). In B16F10 melanoma, previous studies have shown that single-agent treatment with IL-2 is only partially effective, and co-treatment with the anti-melanoma cell antibody TA99 (anti-TRP1 monoclonal antibody) is synergistic with IL-2 5,12,14 and IL-15 (superagonist complex ALT-803) 48 . In long-term survival experiments (8 weeks), Neo-2/15 in combination with TA99 showed substantially reduced toxicity and an overall superior therapeutic effect compared to mouse IL-2 ( Fig. 4e , Extended Data Fig. 2 ), whereas treatment with TA99 alone had little effect. Mice treated with both mouse IL-2 and TA99 steadily lost weight and their overall health declined to the point of requiring euthanasia, whereas little decline was observed with the combination of Neo-2/15 and TA99 ( Fig. 4e ). Consistent with a therapeutic benefit, Neo-2/15 treatment led to significantly increased intratumoural CD8:T reg ratios ( Fig. 4f , Extended Data Fig. 1 ), which are known to correlate with effective antitumour immune responses 49 . The increases of CD8:T reg ratios with Neo-2/15 treatment are dose-and antigen-dependent ( Fig. 4f ), which is in agreement with the enhanced therapeutic effects observed at higher doses and in combination with TA99 (Extended Data Fig. 2 ). Collectively, these data show that Neo-2/15 exhibits the predicted homeostatic benefit derived from its IL-2-like immunostimulatory activity, but without the adverse effects associated with preferential binding to CD25 + cells. These enhanced properties and low toxicity could enable routine use of Neo-2/15 for indications for which IL-2 is not broadly used, such as to enhance CAR-T cell therapies (Extended Data Fig. 4 ). The activation of pSTAT5 signalling in naive mouse peripheral blood lymphocytes (CD8 + T and B cells) observed an hour after exposure to Neo-2/15 was markedly reduced after three hours (Extended Data Fig. 6 ), suggesting that the efficacy of Neo-2/15 can be increased using standard approaches for extending circulation half-life, such as PEGylation 50 .
De novo design of protein mimetics has the potential to transform the field of protein-based therapeutics, enabling the development of molecules that improve on biology by enhancing therapeutic properties and reducing side effects, not only for cytokines, but for almost 
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any biologically active molecule with known or accurately predictable structure. Because of the incremental nature of current traditional engineering approaches (for example, 1-3 amino acid substitutions, chemical modification at a single site), most of the shortcomings of the parent molecule are inevitably passed on to the resulting engineered variants, often in an exacerbated form. By building mimics completely from scratch, these shortcomings can be avoided. Unlike recombinant IL-2 and its engineered variants, Neo-2/15 is highly expressed in E. coli ( Supplementary Fig. 13 ), retains activity at high temperature, does not interact with IL-2Rα, and is robust to substantial sequence changes (Extended Data Fig. 8 ), which may enable the engineering of new functions. Immunogenicity against the de novo designed proteins appears to be low, probably because of their small size and high stability 35 , and in contrast to incremental variants of human IL-2, any antibody response mounted against mimetics is unlikely to cross-react with its natural (cytokine) counterpart. Because of their high stability and robustness, along with their tailored interaction surfaces, de novo designed protein mimetics are likely to be particularly powerful for developing next-generation therapeutics that combine different protein functionalities.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-018-0830-7. . n = 6 (no tx); n = 8 (MmIL-2; Neo-2/15). c, Neo-2/15 does not have detectable immunogenicity. Mice were immunized with Neo-2/15 (red, n = 10) or mouse IL-2 (grey, n = 10) (14 days of daily intraperitoneal injections, 10 µg day −1 ). IgG was detected by enzymelinked immunosorbent assay (ELISA). Anti-Neo-2/15 polyclonal antibody was used as a positive control (black, n = 2) and did not cross-react with mouse or human IL-2. White, negative control (n = 2). OVA, ovalbumin. d, Neo-2/15 is more effective than mouse IL-2 in a colorectal cancer model (CT26 
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Computational design of de novo cytokine mimetics. The design of de novo cytokine mimetics began by defining the structure of human IL-2 in the quaternary complex with the human IL-2Rβγ c receptor as the template for the design. After inspection, the residues composing the binding site were defined as hotspots. The structure was fed into the new mimetic design protocol that is programmed in PyRosetta, which can automatically detect the core secondary structure elements that compose the target template and produce the resulting de novo mimetic backbones. In brief, the mimetic building algorithm works as follows. For the first generation of designs, each of the core elements was idealized by reconstruction using loops from a clustered database of highly ideal fragments (fragment size = 4 amino acids, see Data availability). After idealization, the mimetic building protocol aims to reconnect the idealized elements by pairs in all possible combinations. To do this, it uses combinatorial fragment assembly of sequence-agnostic fragments from the database, followed by Cartesian-constrained backbone minimization for potential solutions (that is, where the N and C ends of the built fragment are close enough to link the two secondary structures). After minimization, the solutions are verified to contain highly ideal fragments (that is, that every overlapping fragment that composes the two connected elements is also contained within the database) and that no backbone clashes with the target (context) receptor. Successful solutions were then profiled using the same database of fragments in order to determine the most probable amino acids at each position (this information was encoded as metadata on each design). Next, solutions for pairs of connected secondary structures were combinatorially recombined (by using graph theory-connected components) to produce fully connected backbones. Since the number of solutions grows exponentially with each pair of elements, at each fragment combination step we ranked the designs to favour those with shorter interconnections between pairs of secondary structure core elements (that is, effectively with shorter loops), and kept only the top solutions. Fully connected backbone solutions were profiled by layer (interface, core, non-core surface, surface) in order to restrict the identities of the possible amino acids to be layer-compatible. Finally, all the information on hotspots, compatible built-fragment amino acids and layers was combined (hotspot has precedence to amino acid probability, and amino acid probability took precedence to layer) and output as Rosetta resfiles (specific for a given de novo mimic backbone result). These backbones and their corresponding resfiles were then passed to RosettaScripts for flexible backbone design and filtering ( Supplementary  Information, Appendix A) . For the second generation of designs, we followed two approaches. In the first approach, we simply executed Rosetta sequence redesigns of our best first generation optimized design (G1_neo2_40_1F, Supplementary  Information, Appendix B) . In the second approach, we engineered new mimetics using G1_neo2_40_1F as the target template. The mimetic design protocol in this second generation was similar to the one described for the first generation, but with two key differences. First, the core elements (that is, those that are secondary structures) were no longer built from fragments, but instead by discovering parametric equations of repetitive phi and psi angles (omega fixed to 180°) that result in secondary structures that recapitulated each of the target helices as close as possible. Second, a 'pitch' on the phi and psi angles was allowed every 3rd residue in order to allow the helices the possibility to have curvature (final angle parameters: H1: phi = −60.4, psi = −45.8, phi_pitch = −1.0, psi_pitch = 2.0; H2: phi = −64.5, psi = −38.4, phi_pitch = 4.0, psi_pitch = −8.0; H3: phi = −64.6, psi = −40.6, phi_pitch = 0.0, psi_pitch = 0.0; H4: phi = −64.3, psi = −41.7, phi_pitch = 0.0, psi_pitch = 0.0). By using these parametric equations, the algorithm can variate the length of each of the core-elements up to ±8 amino acids (compared to the input template). Reductions in the size of the core elements were not allowed to remove hotspots from the binding site. All length variations of the core elements were reconnected with loops from a clustered database of highly ideal loops (fragment size of 7 amino acids). The rest of the design algorithm is in essence similar to the one followed in the generation one. However, the implementation of the second generation algorithm is more convenient, because the input PDB incorporates PDBInfoLabels metadata to define the hotspots, and subsequently, it uses this information to integrate the loop amino acids-preferences, layers, and hotspots into the final output(s) as PDBInfoLabels metadata. This information can be conveniently used for the subsequent step of sequence design with RosettaScripts ( Supplementary Information, Appendix C) . The Rosetta energy functions used for sequence design were 'talaris2013' and 'talaris2014' , for the first and second generation of designs, respectively.
The databases of highly ideal fragments used for the design of the backbones for the de novo mimetics were constructed with the Rosetta application 'kcenters_clustering_of_fragments' using an extensive database of non-redundant (publicly available) protein structures from the RCSB protein data bank, which was comprised of 16,767 PDB structures for the 4-mer database used in the first generation of designs, and of 7,062 PDB structures for the 7-mer database used for the second generation designs (see Code availability). The computational algorithm for designing the second generation de novo mimics is available (see Code availability). Yeast display. Yeast were transformed with genes encoding the proteins to be displayed together with a linearized pETcon3 vector. The vector was linearized by 100-fold overdigestion by NdeI and XhoI (New England Biolabs) and then purified by gel extraction (Qiagen). The genes included 50 bases of overlap with the vector on both the 5′ and 3′ ends, such that homologous recombination would place the genes in frame between the AGA2 gene and the Myc tag on the vector. Yeast was grown in C-Trp-Ura medium before induction in SGCAA medium as previously described 34, 35, 51 . After induction for 12-18 h, cells were washed in chilled display buffer (50 mM NaPO 4 pH 8, 20 mM NaCl, 0.5% BSA) and incubated with varying concentrations of biotinylated receptor (either human or mouse IL-2Rα, IL-2Rβ or γ c ) while being agitated at 4 °C. After approximately 30 min, cells were washed again in a chilled buffer and then incubated on ice for 5 min with a FITCconjugated Myc antibody (1 µl per 3 × 10 6 cells) and streptavidin-phycoerythrin (1 µl per 100 µl volume of yeast). Yeast was then washed and counted by flow cytometry (Accuri C6) or sorted by fluorescence-activated cell sorting (FACS) (Sony SH800). Mutagenesis and affinity maturation. Site-saturation mutagenesis (SSM) libraries were constructed from synthetic DNA from Genscript. For each amino acid on each design template, forward primers and reverse primers were designed such that PCR amplification would result in a 5′ PCR product with a degenerate NNK codon and a 3′ PCR product, respectively. Amplification of 'left' and 'right' products by COF and COR primers yielded a series of template products each consisting of a degenerate NNK codon at a different residue position. For each design, these products were pooled to yield the SSM library. SSM libraries were transformed by electroporation into conditioned Saccharomyces cerevisiae strain EBY100 cells, along with linearized pETcon3 vector, using the previously described protocol 52 . For details of the primers used in the creation of SSM libraries, see Supplementary  Tables 5, 6 .
Combinatorial libraries were constructed from synthetic DNA from Genscript containing ambiguous nucleotides and similarly transformed into a linearized pETcon3 vector. For details of the primers used in the creation of combinatorial libraries see Supplementary Tables 7, 8 . Protein expression. Genes encoding the designed protein sequences were synthesized and cloned into pET-28b(+) E. coli plasmid expression vectors (GenScript, N-terminal 6× His-tagged followed by a thrombin cleavage site. For all the designed proteins, the sequence of the N-terminal tag used is MGSSHHHHHHSSGLVPRGSHM (unless otherwise noted), which is followed immediately by the sequence of the designed protein. Plasmids were then transformed into chemically competent E. coli Lemo21 cells (NEB). Protein expression was performed using terrific broth and M salts, cultures were grown at 37 °C until A 600 nm reached approximately 0.8, then expression was induced with 1 mM isopropyl β-d-thiogalactopyranoside (IPTG), and the temperature was lowered to 18 °C. After expression for approximately 18 h, cells were harvested and lysed with a Microfluidics M110P microfluidizer at 18,000 psi, then the soluble fraction was clarified by centrifugation at 24,000g for 20 min. The soluble fraction was purified by Immobilized Metal Affinity Chromatography (Qiagen) followed by FPLC size-exclusion chromatography (Superdex 75 10/300 GL, GE Healthcare). The purified Neo-2/15 was characterized by mass spectrum verification of the molecular weight of the species in solution (Thermo Scientific), size-exclusion chromatography-multi-angle laser light scattering (SEC-MALLS) in order to verify monomeric state and molecular weight (Agilent, Wyatt), SDS-PAGE, and endotoxin levels (Charles River).
Human and mouse IL-2 complex components including human IL-2 (residues 1-133), human IL-2Rα (residues 1-217), human IL-2Rβ (residues 1-214), human IL-2Rγ c (residues 1-232), mouse IL-2 (residues 1-149), mouse IL-2Rα ectodomain (residues 1-213), mouse IL-2Rβ ectodomain (residues 1-215), and mouse γ c ectodomain (residues 1-233) were secreted and purified using a baculovirus expression system, as previously described 39, 43 . For the zippered human IL-2Rβγ c heterodimer, the aforementioned extracellular domain residues for the human/mouse IL-2Rβ and human/mouse IL-2Rγ c were separately cloned into baculovirus expression constructs containing 3C protease-cleavable basic and acidic leucine zippers, respectively, for a high-fidelity pairing of the receptor subunits, as described previously 53 . The IL-2Rβ and IL-2Rγ c constructs were transfected independently and their corresponding viruses were co-titrated to determine optimal infection ratios for equivalent expression of the two chains. Insect cell secretion and purification proceeded as described for IL-2 cytokine and receptor subunits. All proteins were purified to >98% homogeneity with a Superdex 200 sizing column (GE Healthcare) equilibrated in Hepes-buffered saline (HBS). Purity was verified by SDS-PAGE analysis. For expression of biotinylated human IL-2 and mouse IL-2 receptor subunits, proteins containing a C-terminal biotin acceptor peptide (BAP, LNDIFEAQKIEWHE) were expressed and purified as described by Ni-NTA affinity chromatography and then biotinylated with the soluble BirA ligase enzyme in 0.5 mM bicine pH 8.3, 100 mM ATP, 100 mM magnesium acetate, and 500 mM biotin (Sigma). Excess biotin was removed by size-exclusion chromatography on a Superdex 200 column equilibrated in HBS. Neo-2/15 crystal and co-crystal structures. C-terminally 6× His-tagged endoglycosidase H (endoH) and mouse IL-2Rβ and IL-2Rγ c were expressed separately in High Five cells using a baculovirus system as previously described 52 . Cells expressing IL-2Rγ c were grown in the presence of 5 µM kifunensine. After approximately 72 h, the secreted proteins were purified from the medium by passing over a Ni-NTA agarose column and eluted with 200 mM imidazole in HBS buffer (150 mM NaCl, 10 mM HEPES pH 7.3). EndoH was exchanged into HBS buffer by diafiltration. Mouse IL-2Rγ c was deglycosylated by overnight incubation with 1:75 (w/w) endoH. Mouse IL-2Rβ and IL-2Rγ c were further purified and buffer was exchanged by FPLC using an S200 column (GE Life Sciences).
Monomeric Neo-2/15 was concentrated to 12 mg/ml and crystallized by vapour diffusion from 2.4 M sodium malonate pH 7.0, and crystals were harvested and flash frozen without further cryoprotection. Crystals diffracted to 2.0 Å resolution at Stanford Synchrotron Radiation Laboratory beamline 12-2 and were indexed and integrated using XDS 54 . The space group was assigned with Pointless 55 , and scaling was performed with Aimless 56 from the CCP4 suite 57 . Our predicted model was used as a search ensemble to solve the structure by molecular replacement in Phaser 58 , with six protomers located in the asymmetric unit. After initial rebuilding with Autobuild 59 , iterative cycles of manual rebuilding and refinement were performed using Coot 60 and PHENIX 61 .
To crystallize the ternary Neo-2/15-mouse IL-2Rβ-mouse IL-2Rγ c complex, the three proteins were combined in equimolar ratios, digested overnight with 1:100 (w/w) carboxypeptidases A and B to remove purification tags, and purified by FPLC using an S200 column; fractions containing all three proteins were pooled and concentrated to 20 mg/ml. Initial needle-like microcrystals were formed by vapour diffusion from 0.1 M imidazole pH 8.0, 1 M sodium citrate and used to prepare a microseed stock for subsequent use in microseed matrix screening 62 (MMS). After a single iteration of MMS, crystals grown in the same precipitant were cryoprotected with 30% ethylene glycol, harvested and diffracted anisotropically to 3.4 Å × 3.8 Å × 4.1 Å resolution at Advanced Photon Source beamline 23ID-B. The structure was solved by molecular replacement in Phaser using the human IL-2Rβ and IL-2Rγ c structures (PDB ID: 2B5I) as search ensembles. This produced an electron density map into which two poly-alanine α-helices could be manually built. Following rigid-body refinement in PHENIX, electron density for the two unmodelled alpha helices, along with the BC loop and some aromatic side chains, became visible, allowing docking of the monomeric Neo-2/15. Two further iterations of MMS and use of an additive screen (Hampton Research) produced crystals grown by vapour diffusion using 150 nl protein, 125 nl well solution containing 0.1 M Tris pH 7.5, 5% dextran sulfate, 2.1 M ammonium sulfate and 25 nl microseed stock containing 1.3 M ammonium sulfate, 50 mM Tris pH 7.5, 50 mM imidazole pH 8.0, 300 mM sodium citrate. Crystals cryoprotected with 3 M sodium malonate were flash frozen and diffracted anisotropically to 2.5 Å × 3.7 Å × 3.8 Å at Advanced Light Source beamline 5.0.1. After processing the data with XDS, an elliptical resolution limit was applied using the STARANISO server (http://staraniso.globalphasing.org/) as described 63 . Rapid convergence of the model was obtained by refinement against these reflections using TLS and target restraints to the higher resolution human receptor (PDB ID: 2B5I) and Neo-2/15 structures in Buster v.2.10.3 64 , with manual rebuilding in Coot, followed by a final round of refinement in PHENIX with no target restraints. Structure figures were prepared with PyMOL 65 . Software used in this project was installed and configured by SBGrid 66 . Cell lines. Unmodified YT-1 67 and IL-2Rα + YT-1 human NK cells 68 were cultured in RPMI complete medium (RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine, minimum non-essential amino acids, sodium pyruvate, 25 mM HEPES, and penicillin-streptomycin (Gibco)). CTLL-2 cells purchased from ATCC were cultured in RPMI complete with 10% T-STIM culture supplement with ConA (Corning). Twenty-four hours before signalling studies, CTLL-2 cells were resuspended in RPMI lacking T-STIM culture supplement for IL-2 starvation. Viability (>95%) of CTLL-2 cells was verified by trypan blue exclusion (counted in a haemocytometer) immediately before performing the signalling assays. All cells were maintained at 37 °C in a humidified atmosphere with 5% CO 2 . The subpopulation of YT-1 cells expressing IL-2Rα was purified via magnetic selection as described previously 39 . Enrichment and persistence of IL-2Rα expression were monitored by analysis of phycoerythrin (PE)-conjugated anti-human IL-2Rα (BioLegend) antibody binding on an Accuri C6 flow cytometer (BD Biosciences). Cell lines were regularly tested via PCR to ensure the absence of mycoplasma contamination. Circular dichroism. Far-ultraviolet circular dichroism measurements were carried out with an AVIV spectrometer model 420 in PBS (pH 7.4) in a 1 mm path length cuvette with a protein concentration of ~0.20 mg/ml (unless otherwise mentioned in the text). Temperature melts were performed from 25 to 95 °C and monitored absorption signal at 222 nm (steps of 2 °C/min, 30 s of equilibration by step). Wavelength scans (195-260 nm) were collected at 25 °C and 95 °C, and again at 25 °C after fast refolding (~5 min). Binding studies. Surface plasmon resonance (SPR): For IL-2 receptor affinity titration studies, biotinylated human or mouse IL-2Rα, IL-2Rβ, and IL-2Rγ c receptors were immobilized to streptavidin-coated chips for analysis on a Biacore T100 instrument (GE Healthcare). An irrelevant biotinylated protein was immobilized in the reference channel to subtract non-specific binding. Less than 100 response units (RU) of each ligand was immobilized to minimize mass transfer effects. Threefold serial dilutions of human IL-2, mouse IL-2, super-2, or engineered IL-2 mimetics, were flowed over the immobilized ligands for 60 s and dissociation was measured for 240 s. For IL-2Rβγ c binding studies, saturating concentrations of human IL-2Rβ (3 µM) or mouse IL-2Rβ (5 µM) were added to the indicated concentrations of human IL-2 or mouse IL-2, respectively. Surface regeneration for all interactions was conducted using 15 s exposure to 1 M MgCl 2 in 10 mM sodium acetate pH 5.5. SPR experiments were carried out in HBS-P+ buffer (GE Healthcare) supplemented with 0.2% bovine serum albumin (BSA) at 25 °C, and all binding studies were performed at a flow rate of 50 l min −1 to prevent analyte rebinding. Data was visualized and processed using the Biacore T100 evaluation software version 2.0 (GE Healthcare). Equilibrium titration curve fitting and equilibrium binding dissociation (K d ) value determination was implemented using GraphPad Prism assuming all binding interactions to be first order. SPR experiments were reproduced three times with similar results. Biolayer interferometry: binding data were collected in a Octet RED96 (ForteBio) and processed using the instrument's integrated software using a 1:1 binding model. Biotinylated target receptors, either human or mouse IL-2Rα, IL-2Rβ or γ c were functionalized to streptavidin-coated biosensors (SA ForteBio) at 1 µg/ml in binding buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20, 0.5% non-fat dry milk) for 300 s. Analyte proteins were diluted from concentrated stocks into binding buffer. After baseline measurement in binding buffer alone, the binding kinetics were monitored by dipping the biosensors in wells containing the target protein at the indicated concentration (association step) and then dipping the sensors back into baseline/buffer (dissociation). For heterodimeric receptor binding experiments for IL-2Rβγ c , γ c was bound to the sensor while IL-2Rβ was in solution at saturating concentrations (that is, at least ~2.5 fold molar excess over the K d ). STAT5 phosphorylation studies. In vitro studies: Approximately 2 × 10 5 YT-1, IL-2Rα + YT-1, or starved CTLL-2 cells were plated in each well of a 96-well plate and re-suspended in RPMI complete medium containing serial dilutions of human IL-2, mouse IL-2, super-2, or engineered IL-2 mimetics. Cells were stimulated for 15 min at 37 °C and immediately fixed by addition of formaldehyde to 1.5% and 10 min incubation at room temperature. Permeabilization of cells was achieved by resuspension in ice-cold 100% methanol for 30 min at 4 °C. Fixed and permeabilized cells were washed twice with FACS buffer (PBS pH 7.2 containing 0.1% bovine serum albumin) and incubated with Alexa Fluor 647-conjugated anti-STAT5 pY694 (BD Biosciences) diluted 1:50 in FACS buffer for 2 h at room temperature. Cells were then washed twice in FACS buffer and mean fluorescence intensity (MFI) was determined on a CytoFLEX flow cytometer (Beckman-Coulter). Dose-response curves were fitted to a logistic model and half-maximal effective concentration (EC 50 values) and corresponding 95% confidence intervals were calculated using GraphPad Prism data analysis software after subtraction of the MFI of unstimulated cells and normalization to the maximum signal intensity. Experiments were conducted in triplicate and performed three times with similar results. Ex vivo studies: spleens and lymph nodes were collected from wild-type C57BL/6J or B6;129S4-Il2ra tm1Dw (CD25KO) mice purchased from The Jackson Laboratory and made into a single cell suspension in sort buffer (2% fetal calf serum in PBS pH 7.2). CD4 + T cells were enriched through negative selection by staining the cell suspension with biotin-conjugated anti-B220, CD8, NK1.1, CD11b, CD11c, Ter119, and CD19 antibodies at 1:100 for 30 min on ice. Following a wash with sort buffer, anti-biotin MicroBeads (Miltenyi Biotec) were added to the cell suspension at 20 µl per 10 7 total cells and incubated on ice for 20 min. Cells were washed and then resuspended. Negative selection was then performed using EasySep Magnets (STEMCELL Technologies). Approximately 1 × 10 5 enriched cells were added to each well of a 96-well plate in RPMI complete medium with 5% FCS with tenfold serial dilutions of mouse IL-2, super-2, or Neo-2/15. Cells were stimulated for 20 min at 37 °C in 5% CO 2, fixed with 4% PFA and incubated for 30 min at 4 °C. Following fixation, cells were harvested and washed twice with sort buffer and again fixed in 500 µl 90% ice-cold methanol in dH 2 O for 30 min on ice for permeabilization. Cells were washed twice with Perm/Wash Buffer (BD Biosciences) and stained with anti-CD4-PerCP in Perm/Wash buffer (1:300), anti-CD44-Alexa Fluor 700 (1:200), anti-CD25-PE-Cy7 (1:200), and 5 µl per sample of anti-pSTAT5-PE pY694 for 45 min at room temperature in the dark. Cells were washed with Perm/Wash and re-suspended in sort buffer for analysis Article reSeArcH on a BD LSR II flow cytometer (BD Biosciences). Dose-response curves were fitted to a logistic model and EC 50 values and corresponding 95% confidence intervals were determined using GraphPad Prism data analysis software after subtraction of the MFI of untreated cells and normalization to the maximum signal intensity. Experiments were performed in triplicate and repeated three times with similar results. In vivo mouse airway inflammation experiments. Mice (C57BL/6J, The Jackson Laboratory) were inoculated intranasally with 20 µl whole house dust mite antigen (Greer) resuspended in PBS to a total of 23 µg Derp1 per mouse. From days 1-7, mice were given a daily intraperitoneal injection of 20 µg mouse IL-2 in sterile PBS (pH 7.2), a molar equivalent of Neo-2/15 in sterile PBS, or no injection. On Day 8, circulating T cells were intravascularly labelled and tetramer-positive cells were enriched from lymph nodes and spleen or lung as previously described 69 . Both the column flow-through and bound fractions were saved for flow cytometry analysis. Cells were surface stained with antibodies and analysed on a BD LSR II flow cytometer with BD FACSDiva software (BD Biosciences). Antibodies used: FITC anti-Ki67, clone SolA15, PerCP-Cy5.5 anti-CD25, clone PC61, eFluor 450 anti-Foxp3, clone FJK-16S, BV510 anti-CD8, clone 53-6.7, BV605 anti-PD-1, clone J43, BV711 anti-CD4, clone RM4-5, BV786 anti-CD62L, clone MEL-14, PE anti-CD69, clone H1.2F3, PE-CF594 anti-B220, clone RA3-6B2, PE-Cy7 anti-CXCR5, clone 2G8 and BUV395 anti-Thy1.2, clone 53-2.1. All flow cytometry files were analysed using FlowJo 9.9.4 and statistical analysis was performed using Prism 7. All experiments were performed in accordance with the University of Washington Institutional Care and Use Committee guidelines. Colorectal carcinoma in vivo mice experiments. CT26 cells were sourced from the research group of J. Demengeot at Instituto Gulbenkian de Ciência, Portugal. On day 0, 5 × 10 5 cells were injected subcutaneously into the flanks of BALB/c mice purchased from Charles River with 50 µl of a 1:1 mixture of Dulbecco's modified Eagle medium (Gibco) with Matrigel (Corning). Starting on day 6, when tumour volume reached around 100 mm 3 , Neo-2/15 and mouse IL-2 (Peprotech) were administered daily by intraperitoneal (i.p.) injection in 50 µl PBS (Gibco). Mice were euthanized when tumour volume reached 1,300 mm 3 . BALB/c mice were purchased from Charles River. Flow cytometry: all reagents were purchased from Gibco by Life Technologies (Thermo Fisher Scientific) unless stated otherwise. Excised tumours were minced and digested using a mix of collagenase I, collagenase IV (Worthington) and DNase I (Roche) in a shaker for 20 min, 250 r.p.m. at 37 °C. After digestion, samples were passed through a 100-µm cell strainer, and resuspended in cold complete RPMI 1640 medium, supplemented with 10 mM HEPES buffer, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin and complemented with 1% non-essential amino acids (NEAA), 1% GlutaMAX supplement and 10% heat-inactivated FBS (HI FBS). The cell suspensions from the spleens and the inguinal lymph nodes were obtained through the smashing of the tissues against the filter of a 100-µm cell strainer. Cells were resuspended in PBS with 2% FBS and 1 mM EDTA and stained for extracellular markers for 45 min at 4 °C. Cell suspensions were then fixed, permeabilized and stained for intracellular markers using the eBioscience Foxp3 Transcription Factor Staining Buffer Set from ThermoFisher Scientific. Samples were analysed in a BD LSRFortessa flow cytometer equipped with a BD FACSDiva software and data were analysed in FlowJo v.10 software and the statistical analysis was performed using Prism 5. Antibodies (BioLegend) used in colon carcinoma experiments were: CD45-BV510 (30-F11), CD3-BV711 (17A2), CD49b-FITC (DX5), CD4-BV605 (RM4-5), CD8-PECy7 (53-6.7), and Foxp3-APC (FJK-16 s; eBioscience). Fixable Viability Dye eFluor 780 (eBioscience) was used to exclude dead cells. Animals were maintained according to protocols approved by the Direção Geral de Veterinária and iMM Lisboa ethical committee. Melanoma in vivo experiments. B16F10 cells were purchased from ATCC. On day 0, 5 × 10 5 cells were inoculated into the mice (C57BL/6J purchased from Jackson) by subcutaneous injection in 500 µl Hank's balanced salt solution (Gibco). Starting on the specified day, Neo-2/15 or mouse IL-2 (Peprotech) treatments were administered daily by intraperitoneal injection in 200 µl LPS-free PBS (Teknova). Treatment with TA99 (a gift from N. Momin and D. Wittrup, Massachusetts Institute of Technology) at 150 µg per mouse was added later on the day indicated in the text. Mice were euthanized when tumour volume reached 2,000 mm 3 . Flow cytometry: excised tumours were minced, enzymatically digested (Miltenyi Biotec), and passed through a 40-µm filter. Cells from spleens and tumour-draining lymph nodes were dispersed into PBS through a 40-µm cell strainer using the back of a 1-mL syringe plunger. All cell suspensions were washed once with PBS, and the cell pellet was resuspended in 2% inactivated fetal calf serum containing fluorophore-conjugated antibodies. Cells were incubated for 15 min at 4 °C then fixed, permeabilized, and stained using a BioLegend FoxP3 staining kit. Samples were analysed on a BD Fortessa flow cytometer. Antibodies (BioLegend) used in melanoma experiments were: CD45-BV711 (clone 30-F11), CD8-BV650 (53-6.7), CD4-BV421 (GK1.5), TCRβ-BV510 (H57-597), CD25-AF488 (PC61), FoxP3-PE (MF-14). Animals were maintained according to protocols approved by Dana-Farber Cancer Institute (DFCI) Institutional Animal Care and Use Committee. Generation of anti-Neo-2/15 polyclonal antibody. Mice (C57BL/6J purchased from Jackson) were injected intraperitoneally with 500 µg of KO Neo-2/15 in 200 µl of a 1:1 emulsion of PBS and complete Freund's adjuvant. Mice were boosted on days 7 and 15 with 500 µg of KO Neo-2/15 in 200 µl of a 1:1 emulsion of PBS and incomplete Freund's adjuvant. On day 20, serum was collected and recognition of Neo-2/15 was confirmed by ELISA. For the ELISA, plates were coated with Neo-2/15, KO Neo-2/15, or mouse IL-2 mixed with ovalbumin for a total of 100 ng/ well in carbonate buffer. Coated plates were incubated with mouse serum diluted 1:1,000 in PBS. Binding was detected using anti-mouse IgG conjugated to horseradish peroxidase (HRP) and developed with 3,3′,5,5-tetramethylbenzidine (TMB). Results were quantified using absorption at 450 nm. Enzyme-linked immunosorbent assay. High-binding 96-well plates (Corning) were coated overnight at 4 °C with 100 ng/ml of Neo-2/15, mouse IL-2 (Peprotech), HsIL-2 (Peprotech) or ovalbumin (Sigma-Aldrich) in carbonate buffer. Antibody binding to target proteins was detected using HRP-conjugated sheep anti-mouse IgG (GE Healthcare) at 75 ng/ml. Plates were developed with tetramethylbenzidine and HCl. Absorbance was measured at 450 nm with an EnVision Multimode Plate Reader (PerkinElmer). T cell proliferation assay. Cells were isolated from mice (C57BL/6J purchased from Jackson) spleens using the EasySep T Cell Isolation Kit (StemCell Technologies). Cells were plated in RPMI in 96-well culture plates at a density of 10,000 cells/well. Medium was supplemented with regular or heat-treated Neo-2/15, mouse IL-2, or super-2 (as indicated). After 5 days of incubation at 37 °C, cell survival and proliferation were measured by CellTiter-Glo Luminescent Cell Viability Assay (Promega).
In vivo experiments. For T reg expansion experiments (Fig. 4a ), naive C57BL/6 mice were treated daily with Neo-2/15 or mouse IL-2 at the indicated concentrations (n = 2-3 per group). After 14 days, spleens were harvested and analysed by flow cytometry using the indicated markers. For immunogenicity experiments (Fig. 4c ), C57BL/6 mice were inoculated with 5 × 10 5 B16F10 cells by subcutaneous injection. Starting on day 1, mice were treated daily with Neo-2/15 (10 µg) or equimolar mouse IL-2 by intraperitoneal injection (n = 10 for each group). After 14 days, serum (antiserum) was collected and IgG was detected by ELISA in plates coated with 10% fetal bovine serum (negative control), Neo-2/15, mouse IL-2, human IL-2, or ovalbumin as a negative control. Polyclonal mouse IgG against Neo-2/15 (anti-Neo-2/15 polyclonal antibody) was generated using complete Freund's adjuvant in conjunction with KO Neo-2/15, an inactive double point mutant of Neo-2/15: Y14D, F99D. For colorectal cancer experiments (Fig. 4d) , BALB/C mice were inoculated with CT26 tumours. Starting on day 6, mice were treated daily by intraperitoneal injection of mouse IL-2 or Neo-2/15 (10 µg), or left untreated (n = 5 per group); For melanoma experiments (Fig. 4e ), C57BL/6 mice were inoculated with B16 tumours. Starting on day 1, mice were treated daily by intraperitoneal injection of Neo-2/15 (10 µg) or equimolar mouse IL-2 (n = 10 per group). Twice-weekly treatment with TA99 was added on day 3. Mice were euthanized when weight loss exceeded 10% of initial weight or when tumour size reached 2,000 mm 3 ; For CD8 + : T reg ratio in melanoma experiments (Fig. 4f ), C57BL/6 mice were inoculated with B16 tumours and treated by daily intraperitoneal injection as indicated. Treatment with TA99 was started on day 5 and continued twice-weekly. Tumours were collected from mice when they reached 2,000 mm 3 , and were analysed by flow cytometry. The CD8 + :T reg cell ratio was calculated by dividing the percentage of CD45 + TCRβ + cells that were CD8 + by the percentage that were CD4 + CD25 + FoxP3 + .
CAR-T cell in vivo experiments.
In vitro T cell proliferation assay. Primary human T cells were obtained from healthy donors, who provided written informed consent for research protocols approved by the Institutional Review Board of the FHCRC. Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll-Hypaque (Sigma). T cells were isolated using EasySep CD8 or CD4 negative isolation kits (Stemcell Technologies). To stimulate T cells, T cells were thawed and incubated with anti-CD3/CD28 Dynabeads (Gibco) at 1:1 ratio in medium supplemented with 50 IU/ml (3.1 ng/ml) IL-2. Beads were removed after four days of incubation. Stimulated or freshly thawed unstimulated T cells were plated at 30,000 or 50,000 cells/well, respectively, in 96-well format and cultured in indicated concentrations of IL-2 or Neo-2/15 in triplicate. Three days later, proliferation was measured using CellTiter-Glo 2.0. (Promega). In vivo RAJI experiment: the FHCRC Institutional Animal Care and Use Committee approved all mouse experiments. Six-to-eight-week-old NSG mice were obtained from the Jackson Laboratory. RAJI tumour cells (0.5 × 10 6 ) transduced with (ffLuc)-eGFP were injected into the tail vein of NSG mice. Seven days after tumour injection, lentiviral transduced anti-CD19 CAR T cells (0.4 × 10 6 CD4 + , 0.4 × 10 6 CD8 + ) prepared as described 70 were infused intravenously into mice. Human IL-2 or Neo-2/15 at 20 µg/mouse was injected intraperitoneally from day 8 to 16 after tumour injection.
Disulfide-stapling Neo-2/15 to increase its stability and binding potency. Neo-2/15 is highly modular; this makes it possible to further tune its properties. As proof of concept, we designed stability-enhancing disulfide staples that preserve the function of the protein 71 . Two computational design strategies were tested. First, we designed internal disulfide bridges for all pairs of positions with favourable geometrical arrangements inside of Neo-2/15. The four best disulfide-stapled designs (that is, with the most favourable energy and minimal geometric distortion) were recombinantly expressed in E. coli. A design that bridges residues 38-75 (stabilizing helices H3→H2′) was confirmed to be monomeric by sizeexclusion chromatography followed by multi-angle light scattering (SEC-MALS). In the second approach, we remodelled the N-and C-termini of Neo-2/15 to allow the introduction of a single-disulfide staple encompassing the entire protein. We generated a total of 330 models that were then filtered based on fragment quality and disulfide-bond geometry. Finally, the designs were manually inspected and six were selected (representing a diversity of insertion lengths) and experimentally characterized as described above. One design, replacing the terminal residues P and S with the amino acid sequences CNSN and NFQC at the N and C termini, respectively (Extended Data Fig. 3 ) was confirmed to be monomeric by SEC-MALS. The designs from both disulfide-stapling strategies successfully increased the stability of Neo-2/15 (T m > 95 °C) and its binding potency (Extended Data Fig. 3 ). Pharmacodynamics and pharmacokinetics of Neo-2/15 in mice. We assessed the in vivo duration of pSTAT5 signalling response to Neo-2/15 in peripheral blood lymphocytes of naive mice (CD8 and B cells, Extended Data Fig. 6 ). As expected, Neo-2/15 has a substantial effect (similar to mouse IL-2) in CD8 cell signalling 1 h after administration, but as expected from the small size of Neo-2/15, the signalling effect decreases greatly after 3 h (Extended Data Fig. 6 ) and is undetectable after 8 h (data not shown). This suggests that future engineering of Neo-2/15 to extend half-life may be possible; there are a number of approaches such as Fc fusions, site-specific PEGylation (for example, through engineered cysteines, such as those demonstrated in Supplementary Fig. 14) , fusions to targeting domains (for example, mAbs, sdAbs or VHHs 12,72 , DARPins 72 , or de novo designed binding proteins 35, 73, 74 ) that can be used to extend its half-life and would likely translate into improved pharmacokinetics. Molecular dynamics simulations of apo Neo-2/15 and holo Neo-2/15. Molecular dynamics simulations in explicit water solvent initiated from the computational model of apo Neo-2/15 recapitulated the crystallographic structure of (monomeric) apo Neo-2/15 (average r.m.s.d. to crystal structure = 1.9 Å; Extended Data Fig. 7a ). For instance, molecular dynamics simulations initiated from the ternary complex of Neo-2/15 with the mouse IL-2Rβγ c were more likely to sample the crystallographic structure observed for Neo-2/15 in the ternary complex with mouse IL-2Rβγ c , including the outward movement of helices H2′-H4 (Neo-2/15 average r.m.s.d. to crystal structure = 1.4 Å; Extended Data Fig. 7c ). The conformation of Neo-2/15 seems to be stabilized in the ternary complexes (either with the mouse or human receptors; Extended Data Fig. 7c, d ). Molecular dynamics simulations were performed using GROMACS 2018.1 75, 76 with the Amber99SB-ILDN force field 77 . Each system consisted of the protein in a solvated dodecahedron box (minimum initial distance from the protein to the boundary = 1 nm) filled with explicit TIP3P waters 78 and neutralized with Cl − or Na + ions. The solvated systems were energy-minimized using the steepest descent minimization method, followed by equilibration for 200 ps under the NPT ensemble with position restraints (1,000 kJ mol −1 nm −1 , applied on all the heavy atoms of the protein). Pressure coupling to 1 atm was performed with the Berendsen barostat 79 , and the temperature was coupled to 310 K using the velocity-rescaling thermostat. The equilibrated systems were used as starting conformations for production runs. In the case of the monomers, we performed 5 independent production simulations of 100 ns each, and for the complexes bound to any of the IL-2 receptors, we performed 5 independent simulations of 90 ns each. The production simulations were conducted under the NPT ensemble, with the Parrinello-Rahman barostat 80 for pressure coupling to 1 atm. The cut-off for van der Waals and short-range electrostatic interactions was set to 1 nm. Long-range electrostatic interactions were treated with the particlemesh Ewald (PME) summation method 81 , and the Verlet cut-off scheme was used 82 . The LINCS algorithm was used to constrain all chemical bonds and allow an integration time-step of 2 fs. The simulation trajectories were recorded every 20 ps and were analysed using GROMACS. Statistical and power analyses. For statistical test a P value of less than 0.05 considered significant unless otherwise noted. For comparison of fitted curves in cellular phospho-STAT5 signalling assays, differences in EC 50 values were considered statistically significant if their 95% confidence intervals did not overlap. In vivo airway inflammation experiments; comparison of cell populations were performed using a two-tailed t-test. In vivo mouse colon cancer experiments; comparisons of the survival of tumour-bearing mice were performed using the log-rank Mantel-Cox test (95% confidence interval). Comparisons of weight loss in tumour-bearing mice were performed using a two-tailed t-test. In vivo mouse melanoma experiments:
comparisons of the survival of tumour-bearing mice were performed using the log-rank Mantel-Cox test (95% confidence interval). Comparisons of weight loss in tumour-bearing mice were performed using a two-tailed t-test. The minimum group size was determined using G*Power for an expected large effect size (Cohen's d = 1.75). For all the bar plots, the whiskers represent ±s.d. and individual data points are shown (as dots) for experiments where the n < 5. Unless otherwise noted, results were analysed by one-way ANOVA, if significant (95% confidence interval), post hoc t-tests were performed comparing groups, and P values were adjusted for multiple comparisons are reported. Software. The design of de novo protein mimics was performed using the custom Python code 'protein mimic designer' (https://www.python.org), IPython 83 , and using the scientific high-performance modules: PyRosetta 42 , numpy and scipy 84, 85 , matplotlib 86 , sklearn 87 , cython 88 and pandas 89 . Data analyses were performed with custom code in Python and IPhyton. Protein sequence design was performed with Rosetta 40, 41 and RosettaScripts 40 . Protein visualization was performed using PyMOL 56 . Simple protein-protein sequence alignments were performed using BLASTP, and structural based sequence comparisons were performed using MICAN 90 . Sequence logos were generated with WebLogo 91 . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Code availability. The Python implementation of the de novo protein mimetic design algorithm (generation 2) and the clustered fragments database used for designing the de novo protein mimetics are available as part of the Rosetta distribution (https://www.rosettacommons.org) under the submodule 'pyrosetta_ scripts/apps/deNovoProteinDesign/deNovoProteinMimeticsGen2/' . Other code is available upon request.
Data availability
Structures for Neo-2/15 monomer and its ternary complex with mouse IL-2Rβγ c have been deposited in the Protein Data Bank with accession numbers 6DG6 and 6DG5, respectively. Diffraction images have been deposited in the SBGrid Data Bank with accession numbers 587 and 588, respectively, and validation reports are included in the Supplementary Information. Other data and materials are available upon request from the corresponding authors. Survival curves (top) and tumour growth curves (bottom) for C57BL/6 mice that were inoculated with B16 tumours (as in Fig. 4a ) and treated with low (1 µg per mouse per day) or high (10 µg per mouse per day) doses of Neo-2/15. a, Starting on day 1, mice (n = 5 per group) were treated daily with intraperitoneal injection of single agent Neo-2/15 at 1 µg per mouse or equimolar mouse IL-2 (left), or the same treatments in combination with a twice-weekly treatment with TA99 (started on day 5) (right). Mice were euthanized when tumour size reached 2,000 mm 3 . Tumour growth curves show data only for surviving mice and stop if the number of mice in a group fell below 50% of the initial number. The experiments were performed twice with similar results. b, Similar to a, but starting on day 4. Mice (n = 5 per group) were treated daily with intraperitoneal injection of single agent Neo-2/15 at 10 µg per mouse or equimolar mouse IL-2 (left), or the same treatments in combination with a twice-weekly treatment with TA99 (started on day 4) (right). Mice were euthanized when tumour size reached 1,000 mm 3 . The therapeutic effect of Neo-2/15 is dose-dependent (higher doses have a stronger effect) and is potentiated in the presence of the antibody TA99. Tumour growth curves show data only for surviving mice and stop if the number of mice in a group fell below 50% of the initial number. The experiments were performed twice with similar results. c, C57BL/6 mice were immunized with 500 µg KO Neo-2/15 in complete Freund's adjuvant and boosted on days 7 and 15 with 500 µg KO Neo-2/15 in incomplete Freund's adjuvant. Reactivity against KO Neo-2/15 and native Neo-2/15, as well as cross-reactivity with mouse IL-2 were determined by incubation of serum (diluted 1:1,000 in PBS) with plate-bound KO Neo-2/15, Neo-2/15 or mouse IL-2 as indicated. Serum binding was detected using an anti-mouse secondary antibody conjugated to HRP followed by incubation with TMB. Data are reported as optical density at 450 nm. Top, naive mouse serum; bottom, immunized mouse serum. The experiments were performed once. In all the growth curves, data are mean ± s.e.m. Results were analysed by one-way ANOVA (95% confidence interval), except for survival curves that were assessed using the Mantel-Cox test (95% confidence interval).
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Extended Data Fig. 6 | Kinetics of STAT5 phosphorylation with Neo-2/15 treatment. Naive C57BL/6 mice were treated once with 13 µg mouse IL-2 (n = 5) or 10 µg Neo-2/15 (n = 5), or were left untreated (n = 5). Phosphorylation of STAT5 was measured in peripheral blood at the indicated time points by flow cytometry using an anti-pSTAT5 antibody. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
The design of protein mimics was performed using custom code programmed in python and ipython, in combination with the scientific/ high-performance modules: pyrosetta, numpy and scipy, matplotlib, sklearn, cython and pandas. Protein sequence design was performed using Rosetta and RosettaScripts. The computer code and examples are provided along with SI.
Data analysis
Data analysis was performed using custom code programmed in python and ipython and Rosetta, in combination with the scientific/highperformance modules: pyrosetta, numpy and scipy, matplotlib, sklearn, cython and pandas. Protein visualization was performed using PyMOL (PyMOL | pymol.org ).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
